CELLIANT, an infrared responsive technology from materials science trailblazer Hologenix, has completed its 9th peer-reviewed published study.
The new-age performance textile technology CELLIANT is shown in the study – published in the Research Journal of Textile and Apparel – to increase grip strength when used in armbands on people with chronic wrist or elbow pain caused by carpal tunnel syndrome, epicondylitis (commonly known as tennis elbow, golfer’s elbow or baseball elbow) or arthritis.
The study was a randomised double-blind placebo-controlled trial containing 68 people.
The 68 subjects, both males and females aged 21 or older, had a six-month history of chronic wrist or elbow pain. They were tasked with wearing an armband (35 with real CELLIANT and 33 with the placebo fabric) on the affected wrist or elbow for at least 12 hours per day for 14 days. Grip strength was measured by a dynamometer before and after the two-week study.
CELLIANT technology is a patented process for adding micron-sized thermo-responsive quartz, silicon oxide and titanium oxide particles to fibres, in this case polyethylene terephthalate (PET) fibres.
The resulting CELLIANT yarns were woven into armbands containing either 42 per cent CELLIANT PET (active) or zero CELLIANT PET (placebo).
The CELLIANT yarns absorb body heat and re-emit the energy back to the body as infrared radiation, which is non-invasive. In this study, they were found to be effective in increasing grip strength.
The mean grip strength percentage increased over two weeks by 7.8 per cent for the placebo group and 16.8 per cent for the CELLIANT group. “No adverse effects were observed,” claims study.
The study also concludes that CELLIANT armbands are easy to wear, cost-effective and have not been shown to produce any adverse effects, so there should not be any barrier to widespread use. It also suggests that while other types of textile technology might be used to produce IR-emitting fabrics, likely the most efficient way to produce such fabrics is by incorporating ceramic particles into the polymer fibres from which the fabric is woven, as with CELLIANT technology.
The protocol for the study was approved by the IRB of Southern California Institute for Research and Education and registered at clinicaltrials.gov. Ian L. Gordon of Veterans Affairs Long Beach Healthcare System in Long Beach, California, participated in the conception and design of the study, carried out subject recruitment and data collection and took part in the statistical analysis.
On the other hand, Seth Casden, Co-founder and CEO, Hologenix – the company that’s behind the innovation of CELLIANT, participated in the conception and design of the study, provided materials and funding, and helped draft the manuscript.
Michael R. Hamblin of the Laser Research Center, University of Johannesburg – Doornfontein Campus, Doornfontein, South Africa, wrote the manuscript and critically reviewed the data.
Hamblin, who serves on the Hologenix Science Advisory Board and is a world-renowned expert on infrared and light therapy, was supported by the US National Institutes of Health (NIH) grants. “All authors read and approved the final manuscript,” claims the company.